This promotional material is intended for UK Healthcare Professionals (HCPs) experienced in the diagnosis and management of Parkinson’s disease only. Adverse event reporting can be found below
DUODOPA (levodopa/carbidopa intestinal gel)
DUODOPA
(levodopa/carbidopa intestinal gel)
PRODUODOPA (foslevodopa/foscarbidopa solution for infusion)
PRODUODOPA
(foslevodopa/foscarbidopa solution for infusion)
Neurology
Levodopa may activate malignant melanoma, so PRODUODOPA and DUODOPA should not be used in patients with suspicious undiagnosed skin lesions or a history of melanoma.1-3
DUODOPA (levodopa/carbidopa intestinal gel) is indicated for the treatment of advanced levodopa-responsive Parkinson’s disease with severe motor fluctuations and hyperkinesia or dyskinesia when available combinations of Parkinson medicinal products have not given satisfactory results.1
PRODUODOPA (foslevodopa/foscarbidopa solution for infusion) is indicated for the treatment of advanced levodopa-responsive Parkinson’s disease with severe motor fluctuations and hyperkinesia or dyskinesia when available combinations of Parkinson medicinal products have not given satisfactory results.2,3
Some patients may not be suitable for DUODOPA or PRODUODOPA. You are strongly advised to read the Prescribing Information (PI) and Summary of Product Characteristics (SmPC), accessible via the links above, to evaluate patient suitability for DUODOPA and PRODUODOPA.
Please refer to the DUODOPA or PRODUODOPA Summary of Product Characteristics for further information on adverse events, contraindications and special warnings and precautions for use.
References
- DUODOPA (levodopa/carbidopa intestinal gel) SmPC.
- PRODUODOPA (foslevodopa/foscarbidopa solution for infusion) GB SmPC.
- PRODUODOPA (foslevodopa/foscarbidopa solution for infusion) NI SmPC.
Adverse events should be reported. Reporting forms and information can be found at yellowcard.mhra.gov.uk or via the MHRA Yellow Card app, available in the Google Play or Apple App Stores.
Adverse events should also be reported to AbbVie on [email protected]
UK-ABBV-230357. Date of preparation: December 2023
